Skip to Main Content

Amer Zeidan, MBBS

Associate Professor of Internal Medicine (Hematology)

Contact Information

Amer Zeidan, MBBS

Mailing Address

  • Hematology

    333 Cedar Street, PO Box 208028

    New Haven, CT, 06520-8028

    United States

Research Summary

The focus of his clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies.

Extensive Research Description

The focus of his clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. Dr. Zeidan is the principal investigator on several clinical trials in MDS, AML and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies (drugs that stimulate the patient's own immune system) including the immune checkpoint inhibitors to fight blood cancers.

Clinical research; Novel therapies

Coauthors

Research Interests

Hematologic Neoplasms; Translational Medical Research

Selected Publications

Clinical Trials

ConditionsStudy Title
Myeloid and Monocytic LeukemiaA Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Leukemia, otherPhase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Leukemia, otherA Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Leukemia, otherA Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Myeloid and Monocytic LeukemiaThe PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Leukemia, otherA Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release